Imagine using a specialized 'Trojan horse' cell to sneak medicine directly into a tumor. This project uses macrophages—cells that naturally hunt for bad actors—and loads them with a drug payload. Once these cells find the cancer, they deliver the medicine precisely where it's needed, bypassing the resistance that usually makes chemotherapy fail.
Ovarian cancer often becomes platinum-resistant, making it an incurable disease for 15-30% of patients. There is a critical unmet need for therapies that can bypass this resistance and target solid tumors effectively.
A pre-clinical data package for MDC-735, including in vitro cell killing assays and in vivo mouse survival data.
If you are a cell therapy developer dealing with the high failure rate of chemotherapy in ovarian cancer — this project developed the MDC-735 product that shows efficacy in both platinum-sensitive and resistant cancer cells. This allows for a 'ready-to-use' allogeneic product rather than patient-specific treatments.
If you are a drug discovery firm dealing with the challenge of delivering toxic drugs to solid tumors without harming healthy tissue — this project developed a Macrophage-Drug Conjugate (MDC) that transfers drug complexes specifically to cancer cells.
If you are a CRO dealing with the need for validated pre-clinical data packages for Phase I trials — this project developed a complete efficacy, PK, PD, and toxicology package for the MDC-735 product.
Based on available project data, there is no information regarding the cost or pricing of the MDC-735 therapy.
The project aims to create an allogeneic, 'ready-to-use' therapy, which typically suggests a more scalable manufacturing model than autologous therapies, though specific industrial scale data is not provided.
The project objectives specifically include the consolidation of IP as part of the pre-clinical development package for the MDC-735 product.
The project runs until 2026-04-30 and aims to produce a validated product ready for a Phase I clinical trial.
The project notes that ovarian cancer treatment currently involves surgery and chemotherapy; this therapy targets the platinum-resistant stage which often follows these initial treatments.
The project is led by a single Polish SME, Cellis Sp. z o.o., resulting in a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the coordinator is directly responsible for the transition from ERC-funded research to a validated product (MDC-735) ready for clinical trials.
Contact Cellis Spolka z Ograniczona Odpowiedzialnoscia in Poland
Contact us to explore licensing opportunities for the MDC-735 pre-clinical package.
